| Literature DB >> 27596222 |
Sangeeta Sule1, Kevin Fontaine2.
Abstract
BACKGROUND: Children with SLE are known to have higher fat mass compared to their peers but there are no published data regarding exercise capacity as measured by cardiovascular endurance and muscle strength. In our pilot study of ten children with SLE, we sought to examine body composition, cardiovascular endurance, and isometric muscle strength.Entities:
Mesh:
Year: 2016 PMID: 27596222 PMCID: PMC5011901 DOI: 10.1186/s12969-016-0110-8
Source DB: PubMed Journal: Pediatr Rheumatol Online J ISSN: 1546-0096 Impact factor: 3.054
Patient characteristics at study entry
| Characteristic | Value |
|---|---|
| Age, mean (SD) | 15.5 (3.1) |
| Female gender, | 9 (90 %) |
| African American, | 8 (80 %) |
| Mean years with SLE, (SD) | 4.2 (2.3) |
| Malar rash, | 6 (60 %) |
| Kidney disease, | 5 (50 %) |
| Focal proliferative, | 1 (10 %) |
| Membranous, | 1 (10 %) |
| Diffuse proliferative, | 3 (30 %) |
| ANA positive, | 10 (100 %) |
| dsDNA positive, | 9 (90 %) |
| Ro/La positive, | 2 (20 %) |
| Smith positive, | 3 (30 %) |
| Low C3/C4, | 2 (20 %) |
| Elevated ESR/CRP, | 0 (0 %) |
| Anemia, | 0 (0 %) |
| Prednisone | 4 (40 %) |
| Dose | 0.1–0.5 mg/kg/day |
| Duration, mean months, (SD) | 2 (3.1) |
| Hydroxychloroquine, | 10 (100 %) |
| Methotrexate, | 2 (20 %) |
| Mycophenolate mofetil, | 4 (40 %) |
Body composition by dual energy X-ray absorptiometry (DEXA) scan
| Variable | ≥30 % Body Fat | <30 % Body Fat |
| ≤60 % Lean Muscle Mass | >60 % Lean Muscle Mass |
|
|---|---|---|---|---|---|---|
|
|
|
|
| |||
| Mean Age, years ± Standard deviation (SD) | 16.3 ± 2.7 | 12.5 ± 3.5 | 0.4 | 15.7 ± 4 | 15.3 ± 2.7 | 0.8 |
| African American, n | 6 | 2 | 0.4 | 4 | 4 | 0.2 |
| Years of SLE ± SD | 4.1 ± 2.5 | 4.5 ± 0.7 | 0.7 | 3.3 ± 1.6 | 5.5 ± 2.6 | 0.2 |
| Physically Active in the past year | ||||||
| Yes | 6 | 2 | 0.9 | 2 | 6 | 0.1 |
| No | 2 | 0 | 2 | 0 | ||
| Malar rash | ||||||
| Present | 6 | 0 | 0.1 | 4 | 2 | 0.07 |
| Absent | 2 | 2 | 0 | 4 | ||
| Kidney Disease | ||||||
| Present | 4 | 1 | 0.9 | 4 | 1 | 0.04 |
| Absent | 4 | 1 | 0 | 5 | ||
| dsDNA Antibody | ||||||
| Present | 8 | 1 | 0.2 | 4 | 5 | 0.9 |
| Absent | 0 | 1 | 0 | 1 | ||
| Ro/La Antibodies | ||||||
| Present | 2 | 0 | 0.9 | 1 | 1 | 0.9 |
| Absent | 6 | 2 | 3 | 5 | ||
| Smith Antibody | ||||||
| Present | 3 | 0 | 0.9 | 3 | 0 | 0.03 |
| Absent | 5 | 2 | 1 | 6 | ||
| Low C3/C4 | ||||||
| Present | 2 | 0 | 0.9 | 2 | 0 | 0.1 |
| Absent | 6 | 2 | 2 | 6 | ||
| Mean SLEDAI, ± SD | 1.3 ± 1.1 | 0 | 0.06 | 2 ± 1.4 | 0.4 ± 0.2 | 0.07 |
| Prednisone | ||||||
| Taking | 4 | 0 | 0.4 | 3 | 1 | 0.1 |
| Not taking | 4 | 2 | 1 | 5 | ||
| Cumulative prednisone dose, mg (range) | 900 (0–3600) | 0 | 0.1 | 1725 (0–3600) | 50 (0–300) | 0.1 |
| Hydroxychloroquine | ||||||
| Taking | 8 | 2 | -- | 4 | 6 | -- |
| Not taking | ||||||
| Methotrexate | ||||||
| Taking | 2 | 0 | 0.9 | 1 | 1 | 0.9 |
| Not taking | 6 | 2 | 3 | 5 | ||
| Mycophenolate mofetil | ||||||
| Taking | 3 | 1 | 0.9 | 2 | 2 | 0.9 |
| Not taking | 5 | 1 | 2 | 4 | ||
Regression analysis of cardiovascular endurance
| Variable | Coefficient |
|
|---|---|---|
| Age, years | 0.5 | 0.5 |
| African American Race | −9.7 | 0.06 |
| Years of SLE | 0.2 | 0.06 |
| Physically Active | 7.7 | 0.2 |
| Malar rash | −5.6 | 0.2 |
| Kidney Disease | −10 |
|
| dsDNA positive, | −11.6 | 0.1 |
| Ro/La positive | −1.5 | 0.8 |
| Smith positive | −9.9 |
|
| Low C3/C4 | −10.4 |
|
| Prednisone | −9.1 |
|
| Methotrexate | −1.5 | 0.8 |
| Mycophenolate mofetil | −6.5 | 0.1 |
| Body Fat >30 % | −5.4 | 0.3 |
| Muscle mass >60 % | 9.7 |
|